Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Comment by kmilneon Jul 08, 2011 11:26pm

350 Views

Post# 18813472

RE: RE: RE: RE: RE: RE: RE: RE: RE: Paper

Joe Trout..........sounds like you may not be that familiar with the pp process. When the four months are up, a lot of holders will sell the shares, profit or not. Usually they recoup their money, sometimes they will take a loss and sometimes make a profit. But they retain their interest in the company with the warrants which were a freebie.
Maybe you know all this but it sounded like you couldn't understand why anyone would sell.

Bullboard Posts

Changing Europe’s dependency on HREE from China